New developments in the treatment of HIV disease: An overview

Annals of Emergency Medicine

Volumn 33, Issue 5, 1999, Pages 546-555

  Hovanessian, H C ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL ACTIVITY; DRUG EFFECT; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

EID: 0032947894     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-0644(99)70341-0     Document Type: Review

References (71)

1. American Medical Association: JAMA HIV/AIDS Information Center. Available at: www.healthgate.com/choice/AMA/search.html.
2. MA Fischl DD Richman MH Grieco The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex N Engl J Med 317 1987 185 191
3. MA Fischl DD Richman N Hansen The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection Ann Intern Med 112 1990 727 737
4. JD Hamilton PM Hartigan MS Simberkoff A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection N Engl J Med 326 1992 437 443
5. BA Larder G Darby DD Richman HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy Science 243 1989 1731 1734
6. The Delta Coordinating Committee Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals Lancet 348 1996 283 291
7. SM Hammer DA Katzenstein MD Hughes A trial comparing nucleoside monotherapy with combination therapy in HIV- infected adults with CD4 cell counts between 200 and 500 per cubic millimeter N Engl J Med 335 1996 1081 1090
8. LD Saravolatz DL Winslow G Collins Zidovudine alone or in combination with didanosine or zalcitabine in HIV- infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter N Engl J Med 335 1996 1099 1106
9. DZ Rana MN Dudley Clinical pharmacokinetics of stavudine Clin Pharmacokinet 33 1997 276 284
10. JJ Eron SL Benoit J Jemsek Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter: North American HIV Working Party N Engl J Med 333 1995 1662 1669
11. C Katlama D Ingrand C Loveday Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: A randomized controlled comparison with zidovudine monotherapy JAMA 276 1996 118 125
12. S Staszewski C Loveday JJ Picazo Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: A randomized controlled comparison with zidovudine monotherapy JAMA 276 1996 111 117
13. J Bartlett S Benoit VA Johnson Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection: A randomized, double-blind, placebo- controlled trial—North American HIV Working Party Ann Intern Med 125 1996 161 172
14. BA Larder SD Kemp PR Harrigan Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy Science 269 1995 696 699
15. K Gelmon JS Montaner M Fanning Nature, time course and dose dependence of zidovudine-related side effects: Results from the Multicenter Canadian Azidothymidine Trial AIDS 3 1989 555 561
16. RE Walker RI Parker JA Kovacs Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine Ann Intern Med 108 1988 372 376
17. CJ Fichtenbaum DB Clifford WG Powderly Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection J Acquir Immune Defic Syndr Hum Retrovirol 10 1995 169 174
18. CM Perry JA Balfour Didanosine: An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease Drugs 52 1996 928 962
19. BY Nguyen R Yarchoan KM Wyvill Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection J Infect Dis 171 1995 1180 1189
20. Drugs for HIV infection Med Lett Drugs Ther 39 1997 111 116
21. AP Lea D Faulds Stavudine: A review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection Drugs 51 1996 846 864
22. EA Petersen CH Ramirez-Ronda WD Hardy Dose- related activity of stavudine in patients infected with human immunodeficiency virus J Infect Dis 171 Suppl 2 1995 S131 S139
23. HW Murray KE Squires W Weiss Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089 J Infect Dis 171 Suppl 2 1995 S123 S130
24. G Skowron Biologic effects and safety of stavudine: Overview of phase I and II clinical trials J Infect Dis 171 Suppl 2 1995 S113 S117
25. JC Adkins DH Peters D Faulds Zalcitabine: An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection Drugs 53 1997 1054 1080
26. AS Blum GJ Dal Pan J Feinberg Low-dose zalcitabine-related toxic neuropathy: Frequency, natural history, and risk factors Neurology 46 1996 999 1003
27. R van Leeuwen C Katlama V Kitchen Evaluation of safety and efficacy of 3TC (lamivudine) in patients wih asymptomatic or mildly symptomatic human immunodefiency virus infection: A phase I/II study J Infect Dis 171 1995 1166 1171
28. DD Richman D Havlir J Corbeil Nevirapine resistance mutations of human immunodeficiency virus type 1 selected drug therapy J Virol 68 1994 1660 1666
29. D Havlir SH Cheeseman M McLaughlin High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodefiency virus infection J Infect Dis 171 1995 537 545
30. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents June 17, 1998 Department of Health and Human Services, Panel on Clinical Practices for Treatment of HIV Infection Bethesda, MD Available at: http://www.hivatis.org
31. Report of the NIH panel to define principles of therapy of HIV infection & Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents MMWR Morb Mortal Wkly Rep 47 No. RR-5 1998 1 38
32. RT Davey Jr DG Chaitt GF Reed Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients Antimicrob Agents Chemother 40 1996 1657 1664
33. S Vella HIV therapy advances: Update on a proteinase inhibitor AIDS 8 Suppl 3 1994 S25 S29
34. AC Collier RW Coombs DA Schoenfeld Combination therapy with zidovudine, didanosine and saquinavir Antiviral Res 29 1996 99
35. SG Deeks Practical issues regarding the use of antiretroviral therapy for HIV infection West J Med 168 2 1998 133 139
36. SM Hammer KE Squires MD Hughes A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less: AIDS Clinical Trials Group 320 Study Team N Engl J Med 337 1997 725 733
37. B Jarvis D Faulds Nelfinavir: A review of its therapeutic efficacy in HIV infection Drugs 56 1998 147 167
38. DW Cameron M Heath-Chiozzi S Danner Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease: The Advanced HIV Disease Ritonavir Study Group Lancet 351 1998 543 549
39. RM Gulick JW Mellors D Havlir Treatment with indinavir, zidovudine and lamivudine in adults with human immunodefiency virus infection and prior antiretroviral therapy N Engl J Med 337 1997 734 739
40. M Markowitz M Saag WG Powderly A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection N Engl J Med 333 1995 1534 1539
41. SA Danner A Carr JM Leonard A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease N Engl J Med 333 1995 1528 1533
42. JB Kopp KD Miller JA Mican Crystalluria and urinary tract abnormalities associated with indinavir Ann Intern Med 127 1997 119 125
43. H John NJ Muller M Opravil Indinavir urinary stones as origin of upper urinary tract obstruction Urol Int 59 1997 257 259
44. M Daudon L Estepa M Kebede Urinary calculi and crystalluria in HIV+ patients treated with indinavir sulfate Presse Med 26 1997 1612 1615
45. RG Bruce LC Munch AD Hoven Urolithiasis associated with the protease inhibitor indinavir Urology 50 1997 513 518
46. JS Berns RM Cohen M Silverman Acute renal failure due to indinavir crystalluria and nephrolithiasis: Report of two cases Am J Kidney Dis 30 1997 558 560
47. KD Miller E Jones JA Yanovski Visceral abdominal fat accumulation associated with use of indinavir Lancet 351 1998 871 875
48. R Viraben C Aquilina Indinavir-associated lipodystrophy AIDS 12 1998 F37 F39
49. M Dube D Johnson J Currier Protease inhibitor-associated hyperglycaemia [letter] Lancet 350 1997 713 714
50. F Visnegarwala K Krause D Musher Severe diabetes associated with protease inhibitor therapy [letter] Ann Intern Med 127 1997 947
51. J Eastone C Decker New-onset diabetes mellitus associated with use of protease inhibitor [letter] Ann Intern Med 127 1997 948
52. AS Perelson AU Neuman M Markowitz HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time Science 271 1996 1582 1586
53. H Jacobsen M Hanggi M Ott In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies J Infect Dis 173 1996 1379 1387
54. SH Cheeseman D Havlir MM McLaughlin Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodefiency virus J Acquir Immune Defic Syndr Hum Retrovirol 8 1995 141 151
55. CC Carpenter M Fischl SM Hammer MS Hirsch Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society—USA Panel JAMA 280 1998 78 86
56. JW Mellors A Munoz JV Giorgi Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection Ann Intern Med 126 1997 946 954
57. MD Hughes VA Johnson MS Hirsch Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response Ann Intern Med 126 1997 983 985
58. JS Montaner P Reiss D Cooper A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: The INCAS trial JAMA 279 1998 930 937
59. RT D’Aquila MD Hughes VA Johnson Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection Ann Intern Med 124 1996 1019 1030
60. Hicks C, Hass D, Seekins D, et al: A phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of DMP 266 in combination with open-label zidovudine with lamivudine [abstract 698], in Program and Abstracts of 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago.
61. Investigational antiretroviral drugs in adjunct stages of clinical study JAMA 280 1998 78 86 Web Extra. Available at: http://www.ama-assn.org/special/hiv/library/readroom/hiv98/80004a1.htm
62. RH Foster D Faulds Abacavir Drugs 55 1998 729 736
63. SG Deeks A Collier J Lalezari The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: A randomized, double-blind, placebo-controlled trial J Infect Dis 176 1997 1517 1523
64. P Barditch-Crovo J Toole CW Hendrix Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil in HIV-infected patients J Infect Dis 176 1997 406 413
65. JC Adkins D Faulds Amprevanir Drugs 55 1998 837 842
66. J Sahai Risks and synergies from drug interactions AIDS 10 Suppl 1 1996 S21 S25
67. Flexner C: Drugs, drugs and more drugs: Understanding their interactions. Healthcare Communications: 8th Clinical Care Options for HIV Symposium. Available at: http:/www.healthcg.com/hiv/journal/scottsdale98/08.html.
68. M Barry S Gibbons D Back Protease inhibitors in patients with HIV disease: Clinically important pharmacokinetic considerations Clin Pharmacokinet 32 1997 194 209
69. Public Health Service guidelines for the management of health-care worker exposures to HIV & recommendations for postexposure prophylaxis MMWR Morb Mortal Wkly Rep 47 No. RR-7 1998 1 39
70. CDC Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood—France, United Kingdom, and United States, January 1988– August 1994 MMWR Morb Mortal Wkly Rep 44 1995 929 933
71. EM Connor RS Sperling R Gelber Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment N Engl J Med 331 1994 1173 1180